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Population ageing is a major medical, social and economic challenge worldwide. Not surprisingly, identifying drugs and compounds that delay ageing is of widespread importance  ADDIN EN.CITE (Moskalev et al. 2016), in particular, given recent advances in our understanding of the genetics of ageing in model organisms (de Magalhaes et al. 2012). Indeed, dozens of studies have been performed in recent years in model organisms to assay compounds for longevity effects. The growing amount of data being generated increases the complexity of its analysis and the difficulty of placing findings in the context of previous studies. To help researchers study and prioritize drugs and compounds of relevance to ageing, we developed DrugAge, a database of drugs and compounds that modulate ageing. We also present our initial analyses and functional enrichment of DrugAge gene targets.
The DrugAge Database
DrugAge aims to provide high-quality summary data on lifespan-extending drugs and compounds in model organisms. Data was primarily assembled using literature searches (see Experimental Procedures in the Supplementary Information). Additionally, we used other databases and submissions from the scientific community, resulting in 324 research articles. DrugAge data focuses solely on assays done in standard conditions (Experimental Procedures in SI). Only compounds, drugs and substances extending lifespan in a statistically-significant manner in at least one experiment were included, but conflicting and negative results were then also added to those entries to provide a balanced literature survey.
DrugAge is searchable based on fields such as the compound name, species or lifespan effect. The current version (build 2) of the database comprises 1316 lifespan assays using 418 distinct compounds on 27 unique model organisms (including 70 individual strains), in particular worms (481 entries), flies (365 entries), yeast (55 entries) and mice (70 entries). The data is presented as tables and interactive charts (Figure 1). DrugAge is freely available online (http://genomics.senescence.info/drugs/ (​http:​/​​/​genomics.senescence.info​/​drugs​/​​)) and data is also available for download. As we will continue to update DrugAge, we encourage feedback and further data submissions from the research community.
We developed a user-friendly interface to search and retrieve information from DrugAge (Figure 1). Key experimental parameters for each assay (average/median lifespan, maximum lifespan, strain, dosage and gender, if available), citations and a link to the original PubMed record are provided. The data browser also features drug and organism records, enabling detailed exploration of the aggregated results for a specific drug or species. Moreover, we found that 214 of the 418 compounds/substances have a known biological interaction in drug interactions databases (Experimental Procedures in SI). As such, users can identify interacting genes and proteins in tabular form, and in network diagrams.
DrugAge Analyses and Functional Enrichment
We found that the magnitude of mean/median lifespan changes per assay is species-dependent and effects are more modest in mice when compared to lower organisms (Figure 2A). The extent of maximum lifespan changes is more modest and not as dissimilar across species (Figure S1). We also noted a linear correlation (r2 = 0.73) between average/median and maximum lifespan changes (Figure S2). Lastly, we found a strong correlation between average/median (r2 = 0.77) and maximum (r2 = 0.81) lifespan changes in males and females, suggesting a modest sexual dimorphism (Figure S3).
In order to analyze enriched processes in the targets of compounds in DrugAge, we used DGIdb  ADDIN EN.CITE (Wagner et al. 2016) to obtain a list of human gene interacting partners for all drugs in DrugAge (Experimental Procedures in SI). Out of a 418 DrugAge compounds/substances, 90 were found to have a DGIdb record, resulting in a total of 411 distinct genes. Statistically significant enriched terms amongst gene targets of compounds in DrugAge include various functional categories related to glutathione and antioxidant activity, calcium and ion transport and metabolic processes (Figure 2B for top results and Table S1 for full results).
We explored the overlap between DrugAge interacting genes and genes previously associated with ageing. This was carried out by obtaining the 1124 human orthologues of genes that extend lifespan in model organisms using the GenAge database (Tacutu et al. 2013). Of the 1124 genes, 287 (25.5%) were known to interact with drugs in DGIdb  ADDIN EN.CITE (Wagner et al. 2016). Of these, 65 (29.3%) overlap with DrugAge targets (Figure S4), when 38 would be expected by chance. As such, we identified a modest but significant (p-value < 0.01) degree of overlap between the genes arising from the two databases.
Concluding remarks
DrugAge was designed to complement and expand existing databases in the context of ageing. In particular, the Human Ageing Genomic Resources (HAGR), also developed by some of us, offer a collection of online databases for understanding ageing in both humans and model organisms (Tacutu et al. 2013). HAGR focuses mostly on genes, and thus there is a need for a curated database of drugs and compounds that can extend lifespan in model organisms. Existing databases with lifespan-extending drugs include AgeFactDB (http://agefactdb.jenage.de/) (Huhne et al. 2014), in turn based on data from HAGR and SAGEWEB (http://sageweb.org/), and Geroprotectors.org (http://geroprotectors.org/)  ADDIN EN.CITE (Moskalev et al. 2015). DrugAge incorporates data from all these resources and improves on them by providing a more extensive and systematic repertoire of lifespan-extending drugs, compounds and substances. Indeed, we followed the high standards for manual curation, user-friendly interface and performance of HAGR (Tacutu et al. 2013). Besides, DrugAge integrates drug-gene interactions and cross-links to ageing-related genes, allowing a deeper examination of lifespan-extending drugs. Interestingly, we have noted a sharp increase in the number of drug assays carried out yearly post-2000 (Figure S5), indicating the timeliness of DrugAge and of pharmacological interventions in aging.
Our initial analysis of DrugAge reveals various trends and insights. We observed that lifespan-extending effects are more modest in mice than in lower organisms, as would be expected. In addition, we observed a strong correlation between average/median and maximum lifespan changes, as well as between lifespan-extending effects in males and females. The significant but modest overlap between targets of lifespan-extending drugs and known ageing-related genes suggests that some but not most ageing-related pathways have been targeted pharmacologically in longevity studies. Lastly, we explored functions and pathways enriched in the targets of lifespan-extending drugs. The most relevant categories are related to glutathione and antioxidant activity, although a caveat to this analysis is that it does not take into account researcher biases in historically studying particular pathways and proteins (and the drugs targeting them) more than others.
In conclusion, we developed a new database of lifespan-extending compounds and drugs in model organisms that reflect our current knowledge of pharmacological manipulations of ageing. Given its scientific quality and rigour, DrugAge will be the benchmark in the field and will be of great value to researchers.
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Figure 1. Several snapshots of DrugAge’s web interface. (a) Snapshot of the DrugAge browser, accompanied by web interface examples showing: (b) the distribution of drug lifespan effects in C. elegans; (c) average lifespan results for the drug “indolepropionamide”; and (d) an overall species summary breakdown across the database.

Figure 2. A: Violin plot based on the average/median lifespan changes reported on 653 C. elegans, 357 D. melanogaster, 63 M. musculus and 42 S. cerevisiae lifespan assays. B: Top functional annotation clusters of gene targets of compounds in DrugAge. Only clusters with an enrichment score > 4 are shown. Full results in Table S1.
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